Halozyme Therapeutics withdraws its bid to acquire Evotec SE for 2 billion euros due to lack of engagement. Evotec remains focused on its standalone strategy for growth and profitability, despite interest from potential buyers. Stocks react with Halozyme rising and Evotec falling.